A detailed history of Spire Wealth Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Spire Wealth Management holds 6,387 shares of GILD stock, worth $436,870. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,387
Previous 7,339 12.97%
Holding current value
$436,870
Previous $594,000 21.38%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

SELL
$71.58 - $87.29 $68,144 - $83,100
-952 Reduced 12.97%
6,387 $467,000
Q4 2023

Feb 06, 2024

SELL
$73.27 - $83.09 $96,716 - $109,678
-1,320 Reduced 15.24%
7,339 $594,000
Q3 2023

Nov 08, 2023

BUY
$73.94 - $80.67 $34,677 - $37,834
469 Added 5.73%
8,659 $648,000
Q2 2023

Aug 09, 2023

SELL
$76.01 - $86.7 $62,860 - $71,700
-827 Reduced 9.17%
8,190 $631,000
Q1 2023

May 09, 2023

BUY
$77.31 - $88.08 $7,035 - $8,015
91 Added 1.02%
9,017 $748,000
Q4 2022

Feb 03, 2023

BUY
$62.32 - $89.47 $129,314 - $185,650
2,075 Added 30.29%
8,926 $766,000
Q3 2022

Nov 07, 2022

SELL
$59.54 - $68.01 $69,364 - $79,231
-1,165 Reduced 14.53%
6,851 $423,000
Q2 2022

Jul 22, 2022

SELL
$57.72 - $65.01 $183,549 - $206,731
-3,180 Reduced 28.4%
8,016 $495,000
Q1 2022

Apr 18, 2022

SELL
$57.92 - $72.58 $128,350 - $160,837
-2,216 Reduced 16.52%
11,196 $666,000
Q4 2021

Jan 14, 2022

BUY
$64.88 - $73.64 $111,788 - $126,881
1,723 Added 14.74%
13,412 $974,000
Q3 2021

Oct 22, 2021

SELL
$67.69 - $73.03 $20,848 - $22,493
-308 Reduced 2.57%
11,689 $816,000
Q2 2021

Jul 26, 2021

SELL
$63.47 - $69.35 $171,242 - $187,106
-2,698 Reduced 18.36%
11,997 $826,000
Q1 2021

May 21, 2021

BUY
$60.0 - $68.46 $881,700 - $1.01 Million
14,695 New
14,695 $951,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $85.7B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.